TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells, covering 2026-01-15 to 2026-01-15. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) [Phase 1]